{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:13:30Z","timestamp":1788401610833,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015250","name":"NIHR Bristol Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015250","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vaccine.2026.128276","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:58:16Z","timestamp":1771383496000},"page":"128276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Effectiveness of bivalent BA.1 mRNA booster vaccines during the autumn 2022 COVID-19 booster programme in adults aged 50+ in England: observational matched cohort study using OpenSAFELY"],"prefix":"10.1016","volume":"76","author":[{"given":"Paul","family":"Madley-Dowd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsie M.F.","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Hulme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom M.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venexia","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Denholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.C.","family":"Sterne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128276_bb0005","unstructured":"NHS England. NHS COVID-19 vaccine bookings to open to millions of people as autumn booster campaign kicks off [Internet]. 2022; Available from: https:\/\/www.england.nhs.uk\/2022\/09\/vaccine-bookings-to-open-to-millions-of-people-as-autumn-booster-campaign-kicks-off\/."},{"key":"10.1016\/j.vaccine.2026.128276_bb0010","unstructured":"NHS England. Over 65s can now book autumn COVID booster [Internet]. 2022; Available from: https:\/\/www.england.nhs.uk\/2022\/09\/over-65s-can-now-book-autumn-covid-booster\/."},{"key":"10.1016\/j.vaccine.2026.128276_bb0015","unstructured":"NHS England. NHS invites people 50 and over for autumn boosters and flu jab [Internet]. 2022; Available from: https:\/\/www.england.nhs.uk\/2022\/10\/nhs-invites-people-50-and-over-for-autumn-boosters-and-flu-jab\/."},{"issue":"290","key":"10.1016\/j.vaccine.2026.128276_bb0020","article-title":"Lineage replacement and evolution captured by 3 years of the United Kingdom coronavirus (COVID-19) infection survey","volume":"2023","author":"Lythgoe","year":"2009","journal-title":"Proc Biol Sci"},{"key":"10.1016\/j.vaccine.2026.128276_bb0025","unstructured":"Departments of Health & Social Care. JCVI statement on the COVID-19 booster vaccination programme for autumn 2022. 2022 3 September 2022 [cited 2024 14 Aug]; Available from: https:\/\/www.gov.uk\/government\/publications\/covid-19-vaccines-for-autumn-2022-jcvi-advice-15-august-2022\/jcvi-statement-on-the-covid-19-booster-vaccination-programme-for-autumn-2022-update-15-august-2022."},{"key":"10.1016\/j.vaccine.2026.128276_bb0030","unstructured":"Electronic Medicines Compendium. Comirnaty Original\/Omicron BA.4-5 (15\/15 micrograms)\/dose dispersion for injection COVID-19 mRNA Vaccine. 2022 15 Jul 2024 [cited 2024 19 Aug]; Available from: https:\/\/www.medicines.org.uk\/emc\/product\/14457\/smpc."},{"key":"10.1016\/j.vaccine.2026.128276_bb0035","unstructured":"Electronic Medicines Compendium. Spikevax bivalent Original\/Omicron BA.4-5 (50 micrograms\/50 micrograms)\/mL dispersion for injection. 2023 09 May 2024 [cited 2024 19 Aug]; Available from: https:\/\/www.medicines.org.uk\/emc\/product\/14632\/smpc."},{"issue":"7","key":"10.1016\/j.vaccine.2026.128276_bb0040","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.cmi.2023.03.007","article-title":"Immunogenicity of omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up","volume":"29","author":"Barda","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128276_bb0045","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S1473-3099(23)00295-5","article-title":"Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial","volume":"23","author":"Lee","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128276_bb0050","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/infdis\/jiad323","article-title":"Immunogenicity of a 2-dose regimen of Moderna mRNA Beta\/omicron BA.1 bivalent variant vaccine boost in a randomized clinical trial","volume":"228","author":"Rouphael","year":"2023","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128276_bb0055","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1473-3099(23)00140-8","article-title":"Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial","volume":"23","author":"Tan","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128276_bb0060","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa2213082","article-title":"Bivalent omicron BA.1-adapted BNT162b2 booster in adults older than 55 years","volume":"388","author":"Winokur","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128276_bb0065","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/14760584.2023.2158816","article-title":"Public health impact of UK COVID-19 booster vaccination programs during omicron predominance","volume":"22","author":"Mendes","year":"2023","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128276_bb0070","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s40121-024-00965-8","article-title":"Modelling COVID-19 vaccination in the UK: impact of the autumn 2022 and spring 2023 booster campaigns","volume":"13","author":"Mendes","year":"2024","journal-title":"Infect Dis Ther"},{"issue":"48","key":"10.1016\/j.vaccine.2026.128276_bb0075","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2023.28.48.2300173","volume":"28","author":"Chatzilena","year":"2023","journal-title":"Eurosurveillance"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128276_bb0080","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S1473-3099(23)00365-1","article-title":"Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study","volume":"23","author":"Kirsebom","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128276_bb0085","unstructured":"UK Health Security Agency. JCVI advises a spring COVID-19 vaccine dose for the most vulnerable. 2022 21 Feb 2022 [cited 2024 28 Aug]; Available from: https:\/\/www.gov.uk\/government\/news\/jcvi-advises-a-spring-covid-19-vaccine-dose-for-the-most-vulnerable."},{"issue":"6","key":"10.1016\/j.vaccine.2026.128276_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/pds.5815","article-title":"OpenSAFELY: a platform for analysing electronic health records designed for reproducible research","volume":"33","author":"Nab","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2026.128276_bb0095","author":"UK Health Security Agency"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128276_bb0100","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M21-4269","article-title":"Challenges in estimating the effectiveness of COVID-19 vaccination using observational data","volume":"176","author":"Hulme","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2026.128276_bb0105","unstructured":"Office for National Statistics: Geography. Sustainability and transformation plan: Full Extent Boundaries in England (Feb 2017). 2017; Available from: https:\/\/geoportal.statistics.gov.uk\/datasets\/3c60f78c9291491ba0b01a4bf8d78305_0\/explore?location=52.745574%2C-2.060823%2C7.56."},{"key":"10.1016\/j.vaccine.2026.128276_bb0110","unstructured":"UK Health Security Agency. A guide to the COVID-19 autumn programme. 2023 Sep 5 2023; Available from: https:\/\/www.gov.uk\/government\/publications\/covid-19-vaccination-autumn-booster-resources\/a-guide-to-the-covid-19-autumn-programme."},{"issue":"14","key":"10.1016\/j.vaccine.2026.128276_bb0115","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMsm1605385","article-title":"Per-protocol analyses of pragmatic trials","volume":"377","author":"Hernan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128276_bb0120","unstructured":"Kirkwood, B.R. and J.A.C. Sterne, Essential medical statistics, in Essentials (Wiley-Blackwell). Malden, MA: Blackwell Science; 2003."},{"issue":"1","key":"10.1016\/j.vaccine.2026.128276_bb0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128276_bb0130","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2026.128276_bb0135","article-title":"Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged >\/=50 years in Nordic countries: nationwide cohort study","volume":"382","author":"Andersson","year":"2023","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128276_bb0140","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad475","article-title":"Bivalent vaccine effectiveness among adults aged >\/=65 years during the BA.5-predominant period in Japan: the VENUS study","volume":"10","author":"Mimura","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128276_bb0145","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S1473-3099(23)00373-0","article-title":"Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study","volume":"23","author":"Tan","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128276_bb0150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","article-title":"The hazards of hazard ratios","volume":"21","author":"Hernan","year":"2010","journal-title":"Epidemiology"},{"key":"10.1016\/j.vaccine.2026.128276_bb0155","doi-asserted-by":"crossref","unstructured":"Fu, E.L., et al., Starting right: aligning eligibility and treatment assignment at time zero when emulating a target trial. Available at SSRN: https:\/\/ssrn.com\/abstract=5177135, 2025.","DOI":"10.2139\/ssrn.5177135"},{"key":"10.1016\/j.vaccine.2026.128276_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071249","article-title":"Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records","volume":"378","author":"Horne","year":"2022","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128276_bb0165","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/EDE.0000000000001747","article-title":"Effectiveness of mRNA COVID-19 vaccines as first booster doses in England: an observational study in OpenSAFELY-TPP","volume":"35","author":"Horne","year":"2024","journal-title":"Epidemiology"},{"key":"10.1016\/j.vaccine.2026.128276_bb0170","doi-asserted-by":"crossref","first-page":"191","DOI":"10.12688\/wellcomeopenres.18010.1","article-title":"OpenSAFELY: representativeness of electronic health record platform OpenSAFELY-TPP data compared to the population of England","volume":"7","author":"Andrews","year":"2022","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.vaccine.2026.128276_bb0175","unstructured":"Departments of Health & Social Care. JCVI statement on spring 2023 COVID-19 vaccinations, 22 February 2023. 2023 [cited 2025 19 Feb]; Available from: https:\/\/www.gov.uk\/government\/publications\/spring-2023-covid-19-vaccination-programme-jcvi-advice-22-february-2023\/jcvi-statement-on-spring-2023-covid-19-vaccinations-22-february-2023."},{"key":"10.1016\/j.vaccine.2026.128276_bb0180","unstructured":"NHS England. Preparing for a successful spring 2023 COVID-19 booster campaign. 2023 [cited 2025 15 July]; Available from: https:\/\/www.england.nhs.uk\/long-read\/preparing-for-a-successful-spring-2023-covid-19-booster-campaign\/."},{"issue":"1","key":"10.1016\/j.vaccine.2026.128276_bb0185","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/aje\/kwad179","article-title":"Challenges in estimating the effectiveness of 2 doses of Covid-19 vaccine beyond 6 months in England","volume":"193","author":"Horne","year":"2024","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2026.128276_bb0190","unstructured":"NHS Digital (Now NHS England). The NHS England OpenSAFELY COVID-19 service - privacy notice. [cited 2023 4 July]; Available from: https:\/\/digital.nhs.uk\/coronavirus\/coronavirus-covid-19-response-information-governance-hub\/the-nhs-england-opensafely-covid-19-service-privacy-notice."},{"key":"10.1016\/j.vaccine.2026.128276_bb0195","unstructured":"NHS Digital (Now NHS England). Data Security and Protection Toolkit - NHS Digital. [cited 2023 4 July]; Available from: https:\/\/web.archive.org\/web\/20250405100349\/https:\/\/digital.nhs.uk\/services\/data-security-and-protection-toolkit\/data-security-and-protection-toolkit."},{"key":"10.1016\/j.vaccine.2026.128276_bb0200","unstructured":"NHS Digital (Now NHS England). ISB1523: Anonymisation Standard for Publishing Health and Social Care Data. [cited 2023 4 July]; Available from: https:\/\/web.archive.org\/web\/20250430135246\/standards.nhs.uk\/published-standards\/anonymisation-standard-for-publishing-health-and-social-care-data."},{"key":"10.1016\/j.vaccine.2026.128276_bb0205","unstructured":"Secretary of State for Health and Social Care - UK Government. Coronavirus (COVID-19): notice under regulation 3(4) of the Health Service (Control of Patient Information) Regulations 2002 \u2013 general. 2022 [cited 2023 5 July]; Available from: https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-notification-of-data-controllers-to-share-information\/coronavirus-covid-19-notice-under-regulation-34-of-the-health-service-control-of-patient-information-regulations-2002-general--2."},{"key":"10.1016\/j.vaccine.2026.128276_bb0210","unstructured":"Secretary of State for Health and Social Care - UK Government. COVID-19 Public Health Directions 2020: notification to NHS Digital. [cited 2023 4 July]; Available from: https:\/\/web.archive.org\/web\/20250414105355\/https:\/\/digital.nhs.uk\/about-nhs-digital\/corporate-information-and-documents\/directions-and-data-provision-notices\/data-provision-notices-dpns\/opensafely-covid-19-service-data-provision-notice."},{"key":"10.1016\/j.vaccine.2026.128276_bb0215","unstructured":"Health Research Authority. Confidentiality Advisory Group. [cited 2023 4 July]; Available from: https:\/\/web.archive.org\/web\/20250408154826\/https:\/\/www.hra.nhs.uk\/about-us\/committees-and-services\/confidentiality-advisory-group\/."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:45:15Z","timestamp":1775195115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26000848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"alternative-id":["S0264410X26000848"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128276","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of bivalent BA.1 mRNA booster vaccines during the autumn 2022 COVID-19 booster programme in adults aged 50+ in England: observational matched cohort study using OpenSAFELY","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128276"}}